$DGX
Quest Diagnostics Inc

2023 Q4 Form 10-Q Financial Statement

#000102207923000157 Filed on October 25, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $2.288B $2.295B
YoY Change -1.93% -7.68%
Cost Of Revenue $1.548B $1.541B
YoY Change -0.51% -4.76%
Gross Profit $740.0M $754.0M
YoY Change -4.76% -13.13%
Gross Profit Margin 32.34% 32.85%
Selling, General & Admin $400.0M $380.0M
YoY Change -24.67% -18.1%
% of Gross Profit 54.05% 50.4%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $109.0M $111.0M
YoY Change -6.03% 2.78%
% of Gross Profit 14.73% 14.72%
Operating Expenses $462.0M $380.0M
YoY Change -21.83% -18.1%
Operating Profit $278.0M $342.0M
YoY Change 49.46% -12.76%
Interest Expense -$40.00M $41.00M
YoY Change 25.0% 10.81%
% of Operating Profit -14.39% 11.99%
Other Income/Expense, Net $10.00M -$43.00M
YoY Change 66.67% 4.88%
Pretax Income $237.0M $299.0M
YoY Change 117.43% -14.81%
Income Tax $40.00M $68.00M
% Of Pretax Income 16.88% 22.74%
Net Earnings $192.0M $225.0M
YoY Change 90.1% -12.11%
Net Earnings / Revenue 8.39% 9.8%
Basic Earnings Per Share $1.99
Diluted Earnings Per Share $1.70 $1.96
COMMON SHARES
Basic Shares Outstanding 112.4M shares 112.2M shares
Diluted Shares Outstanding 114.0M shares

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $686.0M $143.0M
YoY Change 117.78% -79.57%
Cash & Equivalents $686.0M $143.0M
Short-Term Investments
Other Short-Term Assets $286.0M $207.0M
YoY Change 45.92% 21.05%
Inventory $190.0M $184.0M
Prepaid Expenses
Receivables $1.210B $1.281B
Other Receivables $0.00 $0.00
Total Short-Term Assets $2.372B $1.815B
YoY Change 24.97% -22.24%
LONG-TERM ASSETS
Property, Plant & Equipment $2.418B $1.830B
YoY Change 2.85% 7.21%
Goodwill $7.733B $7.732B
YoY Change 7.11% 7.54%
Intangibles $1.166B $1.219B
YoY Change 6.78% 9.33%
Long-Term Investments $135.0M $130.0M
YoY Change 2.27% -5.8%
Other Assets $198.0M $149.0M
YoY Change 37.5% 12.88%
Total Long-Term Assets $11.65B $11.67B
YoY Change 6.5% 7.14%
TOTAL ASSETS
Total Short-Term Assets $2.372B $1.815B
Total Long-Term Assets $11.65B $11.67B
Total Assets $14.02B $13.48B
YoY Change 9.23% 1.96%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.359B $1.157B
YoY Change -2.65% -20.04%
Accrued Expenses $153.0M $157.0M
YoY Change 0.0% 2.61%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $303.0M $304.0M
YoY Change 15050.0% 15100.0%
Total Short-Term Liabilities $1.815B $1.618B
YoY Change 17.02% 1.0%
LONG-TERM LIABILITIES
Long-Term Debt $4.410B $3.946B
YoY Change 10.86% -0.85%
Other Long-Term Liabilities $1.379B $874.0M
YoY Change 6.0% 11.05%
Total Long-Term Liabilities $5.789B $874.0M
YoY Change 9.66% 11.05%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.815B $1.618B
Total Long-Term Liabilities $5.789B $874.0M
Total Liabilities $7.715B $2.492B
YoY Change 11.1% 4.31%
SHAREHOLDERS EQUITY
Retained Earnings $8.825B $8.711B
YoY Change 6.45% 5.42%
Common Stock $2.322B $2.304B
YoY Change 1.09% 1.32%
Preferred Stock
YoY Change
Treasury Stock (at cost) $4.826B $4.570B
YoY Change 3.27% 7.0%
Treasury Stock Shares
Shareholders Equity $6.307B $6.425B
YoY Change
Total Liabilities & Shareholders Equity $14.02B $13.48B
YoY Change 9.23% 1.96%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income $192.0M $225.0M
YoY Change 90.1% -12.11%
Depreciation, Depletion And Amortization $109.0M $111.0M
YoY Change -6.03% 2.78%
Cash From Operating Activities $527.0M $207.0M
YoY Change 57.78% -58.76%
INVESTING ACTIVITIES
Capital Expenditures $72.00M $105.0M
YoY Change -148.98% -188.98%
Acquisitions $2.000M
YoY Change
Other Investing Activities -$42.00M -$2.000M
YoY Change 55.56%
Cash From Investing Activities -$114.0M -$107.0M
YoY Change -34.48% -9.32%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 130.0M -83.00M
YoY Change -123.85% -82.49%
NET CHANGE
Cash From Operating Activities 527.0M 207.0M
Cash From Investing Activities -114.0M -107.0M
Cash From Financing Activities 130.0M -83.00M
Net Change In Cash 543.0M 17.00M
YoY Change -241.04% -118.89%
FREE CASH FLOW
Cash From Operating Activities $527.0M $207.0M
Capital Expenditures $72.00M $105.0M
Free Cash Flow $455.0M $102.0M
YoY Change -5.41% -83.55%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
947000000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
60000000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
96000000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
28000000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
28000000 usd
us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
234000000 usd
us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
230000000 usd
us-gaap Payments Of Dividends Minority Interest
PaymentsOfDividendsMinorityInterest
41000000 usd
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-4000000 usd
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-19000000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
30000000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-172000000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-172000000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
143000000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
700000000 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
6287000000 usd
CY2023Q2 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
77000000 usd
CY2023Q3 dgx Net Income Loss Excluding Redeemable Noncontrolling Interest
NetIncomeLossExcludingRedeemableNoncontrollingInterest
236000000 usd
CY2023Q3 us-gaap Temporary Equity Net Income
TemporaryEquityNetIncome
1000000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-4000000 usd
CY2023Q3 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
80000000 usd
CY2023Q3 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
11000000 usd
CY2023Q3 dgx Temporaryequity Noncontrollinginterest Decreasefrom Distributionsto Noncontrolling Interest Holders
TemporaryequityNoncontrollinginterestDecreasefromDistributionstoNoncontrollingInterestHolders
2000000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
5000000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
18000000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
12000000 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
6463000000 usd
CY2023Q3 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
76000000 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
5930000000 usd
CY2022Q4 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
77000000 usd
us-gaap Net Income Loss
NetIncomeLoss
662000000 usd
dgx Net Income Loss Excluding Redeemable Noncontrolling Interest
NetIncomeLossExcludingRedeemableNoncontrollingInterest
699000000 usd
us-gaap Temporary Equity Net Income
TemporaryEquityNetIncome
4000000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1000000 usd
us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
241000000 usd
us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
36000000 usd
dgx Temporaryequity Noncontrollinginterest Decreasefrom Distributionsto Noncontrolling Interest Holders
TemporaryequityNoncontrollinginterestDecreasefromDistributionstoNoncontrollingInterestHolders
5000000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
58000000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
28000000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
256000000 usd
CY2023Q3 us-gaap Participating Securities Distributed And Undistributed Earnings Loss Diluted
ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted
2000000 usd
CY2022Q3 us-gaap Participating Securities Distributed And Undistributed Earnings Loss Diluted
ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted
2000000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
223000000 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
254000000 usd
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
112000000 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
116000000 shares
CY2023Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2000000 shares
CY2022Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2000000 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
118000000 shares
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.99
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.20
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.96
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.17
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1000000 shares
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1000000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2000000 shares
us-gaap Payments Of Dividends Minority Interest
PaymentsOfDividendsMinorityInterest
58000000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1187000000 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
20000000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
60000000 usd
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
28000000 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
6463000000 usd
CY2023Q3 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
76000000 usd
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
6450000000 usd
CY2022Q2 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
77000000 usd
CY2022Q3 dgx Net Income Loss Excluding Redeemable Noncontrolling Interest
NetIncomeLossExcludingRedeemableNoncontrollingInterest
275000000 usd
CY2022Q3 us-gaap Temporary Equity Net Income
TemporaryEquityNetIncome
1000000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-8000000 usd
CY2022Q3 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
76000000 usd
CY2022Q3 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
21000000 usd
CY2022Q3 dgx Temporaryequity Noncontrollinginterest Decreasefrom Distributionsto Noncontrolling Interest Holders
TemporaryequityNoncontrollinginterestDecreasefromDistributionstoNoncontrollingInterestHolders
1000000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
7000000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
18000000 usd
CY2022Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
1000000 usd
CY2022Q3 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
400000000 usd
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
6272000000 usd
CY2022Q3 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
77000000 usd
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
6483000000 usd
CY2021Q4 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
79000000 usd
dgx Net Income Loss Excluding Redeemable Noncontrolling Interest
NetIncomeLossExcludingRedeemableNoncontrollingInterest
894000000 usd
us-gaap Temporary Equity Net Income
TemporaryEquityNetIncome
5000000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-17000000 usd
us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
231000000 usd
us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
51000000 usd
dgx Temporaryequity Noncontrollinginterest Decreasefrom Distributionsto Noncontrolling Interest Holders
TemporaryequityNoncontrollinginterestDecreasefromDistributionstoNoncontrollingInterestHolders
7000000 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
21000000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
55000000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
96000000 usd
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
28000000 usd
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
950000000 usd
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
6272000000 usd
CY2022Q3 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
77000000 usd
us-gaap Net Income Loss
NetIncomeLoss
845000000 usd
us-gaap Participating Securities Distributed And Undistributed Earnings Loss Diluted
ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted
4000000 usd
us-gaap Participating Securities Distributed And Undistributed Earnings Loss Diluted
ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted
4000000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
658000000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
841000000 usd
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
112000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
117000000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2000000 shares
us-gaap Nature Of Operations
NatureOfOperations
DESCRIPTION OF BUSINESS<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">    </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Background</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">    </span></div>    Quest Diagnostics Incorporated and its subsidiaries ("Quest Diagnostics" or the "Company") empower people to take action to improve health outcomes.  The Company uses its extensive database of clinical lab results to derive diagnostic insights that reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management.  The Company's diagnostic information services business ("DIS") provides information and insights based on an industry-leading menu of routine, non-routine and advanced clinical testing and anatomic pathology testing, and other diagnostic information services. The Company provides services to a broad range of customers, including patients, clinicians, hospitals, independent delivery networks ("IDNs"), health plans, employers, consumers, and accountable care organizations ("ACOs"). The Company offers the broadest access in the United States to diagnostic information services through its nationwide network of laboratories, patient service centers and phlebotomists in physician offices and the Company's connectivity resources, including call centers and mobile paramedics, nurses and other health and wellness professionals. The Company is the world's leading provider of diagnostic information services. The Company provides interpretive consultation with one of the largest medical and scientific staffs in the industry. The Company's Diagnostic Solutions businesses ("DS") are the leading provider of risk assessment services for the life insurance industry and offer healthcare organizations and clinicians robust information technology solutions.
us-gaap Use Of Estimates
UseOfEstimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
225000000 usd
us-gaap Net Income Loss
NetIncomeLoss
662000000 usd
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
114000000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
114000000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
119000000 shares
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
5.87
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
7.17
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
5.79
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
7.05
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0 shares
us-gaap Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
699000000 usd
us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
513000000 usd
CY2023Q3 us-gaap Business Acquisition Purchase Price Allocation Goodwill Expected Tax Deductible Amount
BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
244000000 usd
CY2023Q3 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
3900000000 usd
CY2022Q4 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
3700000000 usd
CY2023Q2 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.71
CY2023Q1 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.71
CY2023Q3 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.71
CY2022Q4 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.66
CY2022Q3 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.66
CY2022Q2 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.66
CY2022Q1 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.66
CY2023Q1 dgx Stock Repurchase Program Additional Amount Authorized
StockRepurchaseProgramAdditionalAmountAuthorized
1000000000 usd
CY2023Q3 us-gaap Stock Repurchase Program Remaining Authorized Repurchase Amount1
StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
1300000000 usd
us-gaap Stock Issued During Period Shares Treasury Stock Reissued
StockIssuedDuringPeriodSharesTreasuryStockReissued
1100000 shares
us-gaap Stock Issued During Period Shares Treasury Stock Reissued
StockIssuedDuringPeriodSharesTreasuryStockReissued
1600000 shares
CY2023Q3 us-gaap Depreciation
Depreciation
84000000 usd
CY2022Q3 us-gaap Depreciation
Depreciation
81000000 usd
us-gaap Depreciation
Depreciation
249000000 usd
us-gaap Depreciation
Depreciation
240000000 usd
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
27000000 usd
CY2022Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
27000000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
81000000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
81000000 usd
CY2023Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
111000000 usd
CY2022Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
108000000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
330000000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
321000000 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
41000000 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
37000000 usd
us-gaap Interest Expense
InterestExpense
117000000 usd
us-gaap Interest Expense
InterestExpense
112000000 usd
CY2023Q3 us-gaap Interest And Dividend Income Operating
InterestAndDividendIncomeOperating
1000000 usd
CY2022Q3 us-gaap Interest And Dividend Income Operating
InterestAndDividendIncomeOperating
4000000 usd
us-gaap Interest And Dividend Income Operating
InterestAndDividendIncomeOperating
5000000 usd
us-gaap Interest And Dividend Income Operating
InterestAndDividendIncomeOperating
6000000 usd
CY2023Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-40000000 usd
CY2022Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-33000000 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-112000000 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-106000000 usd
CY2023Q3 us-gaap Interest Paid Net
InterestPaidNet
17000000 usd
CY2022Q3 us-gaap Interest Paid Net
InterestPaidNet
32000000 usd
us-gaap Interest Paid Net
InterestPaidNet
97000000 usd
us-gaap Interest Paid Net
InterestPaidNet
110000000 usd
CY2023Q3 us-gaap Income Taxes Paid
IncomeTaxesPaid
99000000 usd
CY2022Q3 us-gaap Income Taxes Paid
IncomeTaxesPaid
5000000 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
233000000 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
187000000 usd
CY2023Q3 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
27000000 usd
CY2022Q3 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
30000000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
27000000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
30000000 usd
CY2023Q3 dgx Treasury Stock Purchasedbut Notyet Paid
TreasuryStockPurchasedbutNotyetPaid
0 usd
CY2022Q3 dgx Treasury Stock Purchasedbut Notyet Paid
TreasuryStockPurchasedbutNotyetPaid
26000000 usd
CY2023Q3 dgx Treasury Stock Purchasedbut Notyet Paid
TreasuryStockPurchasedbutNotyetPaid
0 usd
CY2022Q3 dgx Treasury Stock Purchasedbut Notyet Paid
TreasuryStockPurchasedbutNotyetPaid
26000000 usd
CY2023Q3 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
81000000 usd
CY2022Q3 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
75000000 usd
CY2023Q3 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
81000000 usd
CY2022Q3 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
75000000 usd
CY2023Q3 us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
2000000 usd
us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
736000000 usd
us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
143000000 usd
CY2023Q3 us-gaap Liabilities Assumed1
LiabilitiesAssumed1
0 usd
CY2022Q3 us-gaap Liabilities Assumed1
LiabilitiesAssumed1
0 usd
us-gaap Liabilities Assumed1
LiabilitiesAssumed1
36000000 usd
us-gaap Liabilities Assumed1
LiabilitiesAssumed1
15000000 usd
CY2023Q3 dgx Fair Value Of Net Assets Acquired
FairValueOfNetAssetsAcquired
2000000 usd
dgx Fair Value Of Net Assets Acquired
FairValueOfNetAssetsAcquired
700000000 usd
dgx Fair Value Of Net Assets Acquired
FairValueOfNetAssetsAcquired
128000000 usd
CY2023Q3 dgx Merger Consideration Paid Payable Net
MergerConsiderationPaidPayableNet
0 usd
CY2022Q3 dgx Merger Consideration Paid Payable Net
MergerConsiderationPaidPayableNet
0 usd
dgx Merger Consideration Paid Payable Net
MergerConsiderationPaidPayableNet
-88000000 usd
dgx Merger Consideration Paid Payable Net
MergerConsiderationPaidPayableNet
-18000000 usd
CY2023Q3 us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
2000000 usd
CY2022Q3 us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
0 usd
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
612000000 usd
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
110000000 usd
CY2023Q3 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
0 usd
CY2022Q3 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
0 usd
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
1000000 usd
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
4000000 usd
CY2023Q3 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
2000000 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
611000000 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
106000000 usd
CY2023Q3 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
42000000 usd
CY2022Q3 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
49000000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
143000000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
133000000 usd
CY2023Q3 us-gaap Malpractice Loss Contingency Accrual Undiscounted
MalpracticeLossContingencyAccrualUndiscounted
164000000 usd
CY2022Q4 us-gaap Malpractice Loss Contingency Accrual Undiscounted
MalpracticeLossContingencyAccrualUndiscounted
169000000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2295000000 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2486000000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6964000000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7550000000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
342000000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
392000000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
995000000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
1293000000 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-43000000 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-41000000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-102000000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-167000000 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
299000000 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
351000000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
893000000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
1126000000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
68000000 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
81000000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
208000000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
268000000 usd
CY2023Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
6000000 usd
CY2022Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
6000000 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
18000000 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
41000000 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
237000000 usd
CY2022Q3 us-gaap Profit Loss
ProfitLoss
276000000 usd
us-gaap Profit Loss
ProfitLoss
703000000 usd
us-gaap Profit Loss
ProfitLoss
899000000 usd
CY2023Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
12000000 usd
CY2022Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
20000000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
41000000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
54000000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
225000000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
256000000 usd
us-gaap Net Income Loss
NetIncomeLoss
662000000 usd
us-gaap Net Income Loss
NetIncomeLoss
845000000 usd
CY2023Q3 dgx Revenue From Contract With Customer Excluding Assessed Tax Percent
RevenueFromContractWithCustomerExcludingAssessedTaxPercent
1
CY2022Q3 dgx Revenue From Contract With Customer Excluding Assessed Tax Percent
RevenueFromContractWithCustomerExcludingAssessedTaxPercent
1
dgx Revenue From Contract With Customer Excluding Assessed Tax Percent
RevenueFromContractWithCustomerExcludingAssessedTaxPercent
1
dgx Revenue From Contract With Customer Excluding Assessed Tax Percent
RevenueFromContractWithCustomerExcludingAssessedTaxPercent
1
CY2023Q3 dgx Percentageof Net Revenues
PercentageofNetRevenues
1
CY2022Q3 dgx Percentageof Net Revenues
PercentageofNetRevenues
1
dgx Percentageof Net Revenues
PercentageofNetRevenues
1
dgx Percentageof Net Revenues
PercentageofNetRevenues
1
CY2023Q3 dgx Percentageof Net Accounts Receivable
PercentageofNetAccountsReceivable
1
CY2022Q4 dgx Percentageof Net Accounts Receivable
PercentageofNetAccountsReceivable
1
CY2023Q1 dgx Stock Repurchase Program Additional Amount Authorized
StockRepurchaseProgramAdditionalAmountAuthorized
1000000000 usd
CY2023Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001022079-23-000157-index-headers.html Edgar Link pending
0001022079-23-000157-index.html Edgar Link pending
0001022079-23-000157.txt Edgar Link pending
0001022079-23-000157-xbrl.zip Edgar Link pending
dgx-20230930.htm Edgar Link pending
dgx-20230930.xsd Edgar Link pending
dgx09302023ex22.htm Edgar Link pending
dgx09302023ex311.htm Edgar Link pending
dgx09302023ex312.htm Edgar Link pending
dgx09302023ex321.htm Edgar Link pending
dgx09302023ex322.htm Edgar Link pending
dgx09302023ex991.htm Edgar Link pending
dgx09302023ex992.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
dgx-20230930_lab.xml Edgar Link unprocessable
dgx-20230930_cal.xml Edgar Link unprocessable
dgx-20230930_def.xml Edgar Link unprocessable
dgx-20230930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
dgx-20230930_htm.xml Edgar Link completed
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending